Cargando…
Cohort profile: cholangiocarcinoma screening and care program (CASCAP)
BACKGROUND: Cholangiocarcinoma (CCA) is an extremely aggressive cancer that is usually fatal. Although globally morbidity and mortality are increasing, knowledge of the disease remains limited. The Mekong region of Southeast Asia, and particularly the northeast of Thailand, has by far the highest in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459438/ https://www.ncbi.nlm.nih.gov/pubmed/26054405 http://dx.doi.org/10.1186/s12885-015-1475-7 |
_version_ | 1782375221920006144 |
---|---|
author | Khuntikeo, Narong Chamadol, Nittaya Yongvanit, Puangrat Loilome, Watcharin Namwat, Nisana Sithithaworn, Paiboon Andrews, Ross H. Petney, Trevor N. Promthet, Supannee Thinkhamrop, Kavin Tawarungruang, Chaiwat Thinkhamrop, Bandit |
author_facet | Khuntikeo, Narong Chamadol, Nittaya Yongvanit, Puangrat Loilome, Watcharin Namwat, Nisana Sithithaworn, Paiboon Andrews, Ross H. Petney, Trevor N. Promthet, Supannee Thinkhamrop, Kavin Tawarungruang, Chaiwat Thinkhamrop, Bandit |
author_sort | Khuntikeo, Narong |
collection | PubMed |
description | BACKGROUND: Cholangiocarcinoma (CCA) is an extremely aggressive cancer that is usually fatal. Although globally morbidity and mortality are increasing, knowledge of the disease remains limited. The Mekong region of Southeast Asia, and particularly the northeast of Thailand, has by far the highest incidence of CCA worldwide with 135.4 per 100,000 among males and 43.0 per 100,000 among females being reported in Khon Kaen Province. Most patients are first seen during late stage disease with 5-year survival being less than 10 %. Starting in 1984, control and prevention strategies have been focused on health education. Although early detection can substantially increase 5-year survival, there are currently no strategies to increase early diagnosis. METHODS/DESIGN: The Cholangiocarcinoma Screening and Care Program (CASCAP) is a prospective cohort study comprising two cohorts- the screening and the patient cohorts. For the screening cohort, ultrasound examination will be carried out regularly at least annually to determine whether there is current bile duct and/or liver pathology so that the optimal screening program for early diagnosis can be established. This cohort is expected to include at least 150,000 individuals coming from high-risk areas for CCA. For the patient cohort, it is estimated that about 25,000 CCA patients will be included during the 5-year recruitment period. All CCA patients will be treated according to routine clinical care and followed so that effective surgical treatment can be formulated. This cohort is indeed a conventional cancer registry. Thus, CASCAP is an ongoing project in which the number of participants changes dynamically. DISCUSSIONS: This is the first project on CCA that involves screening the at risk population at the community level. At the time of preparing this report, a total of 85,927 individuals have been enrolled in the screening cohort, 55.0 % of whom have already undergone ultrasound screening, and 2661 CCA cases have been enrolled in the patient cohort. Among the participants of the screening, whose mean age was 53.8 ± 9.8 years, 55.6 % were female, 77.5 % attained primary school as the highest level of education, 79.9 % were farmers, 29.9 %, reported having relatives with CCA, 89.1 % had eaten uncooked fish, and 42.2 % of those who had been tested for liver fluke were found to be infected. |
format | Online Article Text |
id | pubmed-4459438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44594382015-06-09 Cohort profile: cholangiocarcinoma screening and care program (CASCAP) Khuntikeo, Narong Chamadol, Nittaya Yongvanit, Puangrat Loilome, Watcharin Namwat, Nisana Sithithaworn, Paiboon Andrews, Ross H. Petney, Trevor N. Promthet, Supannee Thinkhamrop, Kavin Tawarungruang, Chaiwat Thinkhamrop, Bandit BMC Cancer Study Protocol BACKGROUND: Cholangiocarcinoma (CCA) is an extremely aggressive cancer that is usually fatal. Although globally morbidity and mortality are increasing, knowledge of the disease remains limited. The Mekong region of Southeast Asia, and particularly the northeast of Thailand, has by far the highest incidence of CCA worldwide with 135.4 per 100,000 among males and 43.0 per 100,000 among females being reported in Khon Kaen Province. Most patients are first seen during late stage disease with 5-year survival being less than 10 %. Starting in 1984, control and prevention strategies have been focused on health education. Although early detection can substantially increase 5-year survival, there are currently no strategies to increase early diagnosis. METHODS/DESIGN: The Cholangiocarcinoma Screening and Care Program (CASCAP) is a prospective cohort study comprising two cohorts- the screening and the patient cohorts. For the screening cohort, ultrasound examination will be carried out regularly at least annually to determine whether there is current bile duct and/or liver pathology so that the optimal screening program for early diagnosis can be established. This cohort is expected to include at least 150,000 individuals coming from high-risk areas for CCA. For the patient cohort, it is estimated that about 25,000 CCA patients will be included during the 5-year recruitment period. All CCA patients will be treated according to routine clinical care and followed so that effective surgical treatment can be formulated. This cohort is indeed a conventional cancer registry. Thus, CASCAP is an ongoing project in which the number of participants changes dynamically. DISCUSSIONS: This is the first project on CCA that involves screening the at risk population at the community level. At the time of preparing this report, a total of 85,927 individuals have been enrolled in the screening cohort, 55.0 % of whom have already undergone ultrasound screening, and 2661 CCA cases have been enrolled in the patient cohort. Among the participants of the screening, whose mean age was 53.8 ± 9.8 years, 55.6 % were female, 77.5 % attained primary school as the highest level of education, 79.9 % were farmers, 29.9 %, reported having relatives with CCA, 89.1 % had eaten uncooked fish, and 42.2 % of those who had been tested for liver fluke were found to be infected. BioMed Central 2015-06-09 /pmc/articles/PMC4459438/ /pubmed/26054405 http://dx.doi.org/10.1186/s12885-015-1475-7 Text en © Khuntikeo et al. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Khuntikeo, Narong Chamadol, Nittaya Yongvanit, Puangrat Loilome, Watcharin Namwat, Nisana Sithithaworn, Paiboon Andrews, Ross H. Petney, Trevor N. Promthet, Supannee Thinkhamrop, Kavin Tawarungruang, Chaiwat Thinkhamrop, Bandit Cohort profile: cholangiocarcinoma screening and care program (CASCAP) |
title | Cohort profile: cholangiocarcinoma screening and care program (CASCAP) |
title_full | Cohort profile: cholangiocarcinoma screening and care program (CASCAP) |
title_fullStr | Cohort profile: cholangiocarcinoma screening and care program (CASCAP) |
title_full_unstemmed | Cohort profile: cholangiocarcinoma screening and care program (CASCAP) |
title_short | Cohort profile: cholangiocarcinoma screening and care program (CASCAP) |
title_sort | cohort profile: cholangiocarcinoma screening and care program (cascap) |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459438/ https://www.ncbi.nlm.nih.gov/pubmed/26054405 http://dx.doi.org/10.1186/s12885-015-1475-7 |
work_keys_str_mv | AT khuntikeonarong cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT chamadolnittaya cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT yongvanitpuangrat cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT loilomewatcharin cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT namwatnisana cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT sithithawornpaiboon cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT andrewsrossh cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT petneytrevorn cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT promthetsupannee cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT thinkhamropkavin cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT tawarungruangchaiwat cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT thinkhamropbandit cohortprofilecholangiocarcinomascreeningandcareprogramcascap AT cohortprofilecholangiocarcinomascreeningandcareprogramcascap |